ArticleBasic and clinical andrology2026
A case of secretory azoospermia: is valganciclovir responsible?
Article in Basic and clinical andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValganciclovir, the prodrug of ganciclovir, is an antiviral agent targeting herpes viruses. It is indicated for the prophylaxis or treatment of cytomegalovirus infections in immunocompromised patients. Pre-clinical studies state ganciclovir as a mutagenic, teratogenic, reprotoxic drug that can rarely alter male fertility. CASE PRESENTATION: Mr S. had experienced primo-secondary infertility with his partner for 12 months. He had no significant medical history aside from exertional asthma and achieved semen analysis at age 33, revealing normal sperm concentration (110 million/mL, 383 million/ejaculate) with normal progressive motility (50%). One month after, during a trail race, he reported malignant exertional hyperthermia (41.7°C) leading to multi-organ failure and coma and requiring intensive care and an emergency hepatic transplant. Post-transplant, anti-rejection therapy was started including tacrolimus, mycophenolate mofetil, co-trimoxazole, and valganciclovir. Six months after the transplant, he undertook sperm cryopreservation. Repeated semen analysis confirmed azoospermia. Semen analysis 12 weeks after discontinuation of valganciclovir showed rare motile sperm, allowing cryopreservation. Subsequent analyses showed significant improvement, with concentration reaching 10.1 M/mL 14 weeks later and 70 M/mL 24 weeks later, allowing ICSI with fresh sperm. This resulted in a successful pregnancy and live birth.
conclusionsWe report a case of azoospermia observed after valganciclovir treatment. Based on a review of the literature, the azoospermia observed in this patient could be attributed to valganciclovir. However, alternative explanations such as fever or infectious complications cannot be ruled out. Valganciclovir is reprotoxic and should be replaced with an alternative drug in men planning to conceive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.